Stock Pumpers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stock Pumpers

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Jerseyfish	7/7/2014 11:33:41 AM
	of 1290

GNSZ GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors Phase II clinical trials for lead compound, G-202, are underway in two indications: Hepatocellular carcinoma, or liver cancer Glioblastoma, or brain cancer Experienced and motivated team drives the process: Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic. Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders. Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging. Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen. Strong intellectual property portfolio No milestones or royalty payments owed to third parties. Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next